Our Pricing

Buy Wegovy UK Private Prescription: Complete Clinical Guide

Published on: June 03, 2026

When you buy Wegovy UK private prescription through Cured Pharmacy, you access genuine UK-licensed semaglutide injections from £79.00, with transparent upfront pricing and a free clinical consultation completed in under three minutes. Our UK-registered prescribers assess your eligibility the same day, and discreet delivery reaches most addresses within 48 hours.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the glucagon-like peptide-1 hormone, which regulates appetite by acting on brain receptors that control hunger and food intake.

In the landmark STEP 1 trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most significant weight loss outcomes observed in pharmaceutical trials for obesity treatment. Patients typically notice reduced appetite within the first week, though maximum effects develop gradually as the dose escalates over 16 to 20 weeks.

The once-weekly injection format improves adherence compared to daily treatments, and the prefilled pen design requires no preparation or mixing. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that Wegovy works most effectively when combined with a reduced-calorie diet and increased physical activity, as demonstrated across all STEP trial protocols.

Wegovy Dosing Schedule and Titration

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects while optimising weight loss outcomes. The standard titration begins at 0.25 mg weekly for four weeks, increasing monthly through 0.5 mg, 1 mg, and 1.7 mg, before reaching the maintenance dose of 2.4 mg weekly [2].

This gradual escalation allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation. Rushing the titration increases the likelihood of nausea, vomiting, and treatment discontinuation. If you experience persistent side effects at any stage, your UK prescriber may recommend staying at your current dose for an additional four weeks before advancing.

Each Wegovy pen contains four weekly doses at the prescribed strength, meaning you'll receive one pen per month during the escalation phase. Once you reach the 2.4 mg maintenance dose, you continue at this level indefinitely, subject to ongoing prescriber review and clinical response.

What Happens If You Miss a Dose?

If you miss a Wegovy injection and fewer than five days have passed since your scheduled dose, take it as soon as you remember. If more than five days have elapsed, skip the missed dose entirely and resume your regular schedule with the next planned injection [2]. Never double up doses to compensate for a missed injection, as this significantly increases the risk of gastrointestinal adverse effects.

Private Prescription vs NHS Access for Wegovy

NHS England began limited Wegovy rollout in 2023 through specialist weight management services, but eligibility criteria remain restrictive and waiting lists extend beyond 12 months in most regions. NHS access typically requires referral from your GP to a tier 3 weight management programme, documented evidence of previous weight loss attempts, and specific BMI thresholds with comorbidities.

Private prescription routes through registered UK online pharmacies offer immediate clinical assessment without referral requirements or waiting periods. At Cured Pharmacy, our UK-registered prescribers assess your eligibility based on MHRA licensing criteria: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related condition such as type 2 diabetes, hypertension, or obstructive sleep apnoea.

The private route provides continuity of supply independent of NHS capacity constraints, which became particularly evident during the 2023-2024 Wegovy shortage when NHS allocations were prioritised over private prescriptions. Our transparent pricing model shows costs upfront before you complete your clinical assessment, and we guarantee UK's lowest prices on all weight loss treatments.

Clinical Assessment Process at Cured Pharmacy

Your free online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications to GLP-1 therapy. Our UK prescribers review your assessment the same day, and approved prescriptions reach our dispensary within hours. You'll receive tracking information as soon as your Wegovy pens are dispatched in 100% discreet packaging.

Wegovy Side Effects and Management Strategies

The most common side effects of Wegovy affect the gastrointestinal system, reflecting semaglutide's mechanism of slowing gastric emptying. In the STEP trials, nausea occurred in 44% of participants, diarrhoea in 30%, vomiting in 24%, and constipation in 24% [1]. These effects typically emerge during dose escalation and diminish over time as your body adapts.

Practical management strategies significantly reduce the severity and duration of GI side effects. Eat smaller, more frequent meals rather than three large meals daily. Avoid high-fat foods, which delay gastric emptying further and exacerbate nausea. Stay well-hydrated, particularly if you experience vomiting or diarrhoea. Many patients find that taking their weekly injection in the evening reduces daytime nausea.

Rare but serious adverse effects include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications [2]. Contact your prescriber immediately if you develop severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans.

Wegovy vs Alternative Weight Loss Treatments

The UK weight loss medication landscape includes several prescription options, each with distinct mechanisms and clinical profiles. Wegovy represents the current gold standard for pharmaceutical weight management based on trial outcomes, but individual response varies and some patients may benefit more from alternative treatments.

Tirzepatide-based treatments activate both GIP and GLP-1 receptors, producing greater average weight loss than semaglutide in head-to-head trials. The SURMOUNT-1 study demonstrated 20.9% average body weight reduction with the highest tirzepatide dose versus 14.9% with semaglutide in STEP 1 [3]. However, tirzepatide costs more and may cause more frequent gastrointestinal side effects during titration.

Older treatments like orlistat work through fat malabsorption rather than appetite suppression, producing modest weight loss of 3-5% but with different side effect profiles including oily stools and faecal urgency [4]. Orlistat suits patients who cannot tolerate GLP-1 medications or have contraindications to injectable treatments. Your UK prescriber will recommend the most appropriate option based on your medical history, weight loss goals, and treatment preferences.

Switching Between Weight Loss Medications

If you're currently taking another weight loss medication and wish to switch to Wegovy, your prescriber will provide specific guidance based on your current treatment. Generally, you should discontinue your previous medication and begin Wegovy at the 0.25 mg starting dose, following the standard titration schedule. Never take two GLP-1 medications simultaneously, as this increases side effect risk without additional benefit.

Long-Term Wegovy Use and Maintenance

Clinical trial data supports continued Wegovy use for sustained weight management beyond the initial 68-week treatment period studied in STEP 1. The STEP 4 trial specifically examined what happens when patients stop semaglutide after 20 weeks: the discontinuation group regained two-thirds of their lost weight over the subsequent 48 weeks, whilst those continuing treatment maintained their weight loss [5].

This evidence demonstrates that obesity is a chronic condition requiring ongoing pharmacological management in most patients, similar to hypertension or type 2 diabetes. Wegovy does not permanently reset your metabolism or appetite regulation; rather, it provides continuous support for weight maintenance as long as you continue treatment.

At Cured Pharmacy, we structure our repeat prescription service to ensure uninterrupted supply once you reach your maintenance dose. You'll receive automatic reminders when your next prescription is due, and our clinical team conducts regular reviews to assess your ongoing response, side effects, and treatment goals. We monitor for the rare patients who maintain weight loss after discontinuation, but most require indefinite therapy for sustained results.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
5. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Individual results may vary. Weight loss medications work most effectively when combined with a reduced-calorie diet and increased physical activity.